Literature DB >> 27725114

Different etiologies and prognoses of optic neuritis in demyelinating diseases.

Tetsuya Akaishi1, Ichiro Nakashima2, Takayuki Takeshita3, Kimihiko Kaneko4, Shunji Mugikura5, Douglas Kazutoshi Sato6, Toshiyuki Takahashi7, Toru Nakazawa8, Masashi Aoki9, Kazuo Fujihara10.   

Abstract

We compared the clinical features of optic neuritis (ON) that are frequently observed in various central nervous system demyelinating diseases, including multiple sclerosis (MS), anti-aquaporin 4 (AQP4) antibody- and anti-myelin oligodendrocyte glycoprotein (MOG) autoantibody-related diseases. Almost all the AQP4-ON patients were female, whereas half of the MOG-ON patients were male. The ON-onset age was younger in MS-ON and was older in AQP4-ON. The ON-lesion detected using optic MRI in the acute phase was longer in MOG-ON and showed severe swelling and twisting. The worst visual acuity was similar between the diseases; however, the final visual acuity was significantly worse in AQP4-ON.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-MOG autoantibody; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Optic MRI; Optic neuritis; Visual prognosis

Mesh:

Substances:

Year:  2016        PMID: 27725114     DOI: 10.1016/j.jneuroim.2016.09.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

2.  Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis.

Authors:  Ying Peng; Lei Liu; Yuanchu Zheng; Zhixin Qiao; Kai Feng; Jiawei Wang
Journal:  Exp Ther Med       Date:  2018-06-08       Impact factor: 2.447

Review 3.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

4.  Acute Management of Optic Neuritis: An Evolving Paradigm.

Authors:  Lindsay Horton; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2018-09       Impact factor: 3.042

Review 5.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

6.  Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Tetsuya Akaishi; Noriko Himori; Takayuki Takeshita; Kazuo Fujihara; Tatsuro Misu; Toshiyuki Takahashi; Juichi Fujimori; Tadashi Ishii; Masashi Aoki; Toru Nakazawa; Ichiro Nakashima
Journal:  Brain Behav       Date:  2021-02-16       Impact factor: 3.405

7.  Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China.

Authors:  Honglu Song; Huanfen Zhou; Mo Yang; Junqing Wang; Hongjuan Liu; Mingming Sun; Quangang Xu; Shihui Wei
Journal:  J Ophthalmol       Date:  2019-04-01       Impact factor: 1.909

8.  Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.

Authors:  Tetsuya Akaishi; Toshiyuki Takahashi; Tatsuro Misu; Kimihiko Kaneko; Yoshiki Takai; Shuhei Nishiyama; Ryo Ogawa; Juichi Fujimori; Tadashi Ishii; Masashi Aoki; Kazuo Fujihara; Ichiro Nakashima
Journal:  Neurology       Date:  2021-05-12       Impact factor: 11.800

9.  A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies.

Authors:  Lin Zhou; Xiao Tan; Ling Wang; Xiujuan Zhao; Wei Qiu; Hui Yang
Journal:  J Ophthalmol       Date:  2022-03-22       Impact factor: 1.909

10.  Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.

Authors:  Solène Dauby; Dominique Dive; Laurence Lutteri; Cécile Andris; Isabelle Hansen; Pierre Maquet; Emilie Lommers
Journal:  Acta Neurol Belg       Date:  2021-06-07       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.